Pluryal
Pluryal is a Luxembourg-based family-owned medical aesthetics company founded in 1999 that designs and sells hyaluronic acid dermal fillers, polynucleotides-based densifiers, and mesoline serums exclusively to licensed medical professionals in over 70 countries via a global distributor network.
- Company typePrivate
- Founded1999
- HeadquartersLuxembourg, Luxembourg
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Pluryal does
Pluryal (operating through the legal entity MD Skin Solutions SARL) is a Luxembourg-headquartered, family-owned medical aesthetics company founded in 1999. The company designs, develops, and sells two core product lines: Pluryal Mesoline, a range of sterile serums with science-based active ingredients for skin, hair, and body treatments administered via micro-needling rollers, and Pluryal Injectables, comprising hyaluronic acid-based dermal fillers for facial contouring and wrinkle correction alongside hyaluronic acid + polynucleotides-based densifiers for skin repair and collagen stimulation. The portfolio addresses face, hair, body, and intimate aesthetic concerns and is individually inspected before market release under ISO 13485 (medical devices) and ISO 22716 (cosmetics) manufacturing standards. A planned green injectables line is intended to extend the injectable range in response to clean beauty demand.
Pluryal firmographics
Firmographics- Name
- Pluryal
- Legal name
- MD Skin Solutions SARL
- Website
- https://pluryal.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Pluryal is a Luxembourg-based family-owned medical aesthetics company founded in 1999 that designs and sells hyaluronic acid dermal fillers, polynucleotides-based densifiers, and mesoline serums exclusively to licensed medical professionals in over 70 countries via a global distributor network.
- Ownership category
- akta.pro rank
Where Pluryal is headquartered
LocationHeadquarters
- HQ city
- Luxembourg
- HQ country
- Luxembourg
- HQ region
- Europe
Offices1 record
Markets served
Pluryal business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
Revenue model
- Medical Aesthetic Products: Sale of medical aesthetic products including dermal fillers, densifiers, and mesoline sterile serums to licensed healthcare professionals and clinics worldwide.
- Distributor Network: Revenue generated through global distributor network selling Pluryal products to medical aesthetic practitioners in more than 70 countries.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Pluryal product offering
Product offeringCore offering
No factual source-supported description of the company's core offering is present in the provided input. The input block contains no source-attributable product or service description for Pluryal.
Product overview
Pluryal is a European family-owned medical aesthetic company headquartered in Luxembourg that has been designing, developing, and selling products since 1999. The company operates two main product lines: Pluryal Mesoline (a range of sterile serums with science-based active ingredients for skin, hair, and body, delivered via micro-needling) and Pluryal Injectables (hyaluronic acid-based dermal fillers and polynucleotides-based densifiers for facial contouring, wrinkle correction, and skin repair). Treatments cover face, hair, body, and intimate areas across more than 70 countries. The portfolio also includes green injectables planned for launch to meet clean beauty demand.
Differentiator
Problem solved
Functional benefit
Brands
- Mesoline: Range of sterile serums formulated with science-based active ingredients for skin, hair, and body treatments.
- Injectables
Quantifiable outcome
- Treatment duration of 15-30 minutes with no recovery period required
- +2 more outcomes
Companies that use Pluryal
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles1 record
Pluryal technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Pluryal partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Pluryal AffiliatescoreAffiliated distributors in various countries worldwide responsible for distributing Pluryal products and responding to local customer requests.
Scale indicators4 records
Recent moves6 records
Expansion highlights4 records
Pluryal competitors and assessment
Company assessmentBroad incumbents
- Galderma: Global dermatology and aesthetics major with leading hyaluronic acid filler (Restylane) and biostimulator (Sculptra) portfolios sold through medical professionals — directly competes with Pluryal Fillers and Densifiers across face and skin indications.
- AbbVie (Allergan Aesthetics): Owns the Juvéderm hyaluronic acid filler family and Botox, the dominant aesthetics franchise globally — competes head-to-head with Pluryal Injectables across facial contouring and wrinkle correction indications.
- Merz Aesthetics: Markets the Belotero HA filler and Radiesse calcium hydroxylapatite biostimulator, overlapping directly with Pluryal's filler and densifier offerings to plastic surgeons and dermatologists.
Direct peers
- Teoxane: Swiss-based aesthetics company selling the Teosyal range of hyaluronic acid fillers and mesotherapy products through a global distributor model to medical practitioners — closely comparable in size, technology, and go-to-market approach to Pluryal.
- Sinclair Pharma: European aesthetics company with HA filler (MaiLi) and collagen-stimulator (Ellansé) lines distributed globally to aesthetic practitioners — comparable mid-sized competitor in the same biostimulator-plus-filler category as Pluryal.
- Croma-Pharma: Austrian family-owned aesthetics firm selling Princess HA fillers and a broad mesotherapy portfolio to physicians in 70+ countries — directly comparable in family-owned structure, distributor-led model, and product breadth to Pluryal.
- IBSA Derma: Division of IBSA Group marketing Profhilo (HA-based skin remodeling) and other injectable aesthetics products to practitioners — directly competes with Pluryal's densifier proposition of HA-based bio-remodeling for skin quality.
Emerging players
- Revance Therapeutics: US aesthetics company with the RHA Collection of resilient HA fillers and the DaxibotulinumtoxinA neuromodulator — competes in the premium injectable segment that Pluryal targets, though focused on the US market.
- Prollenium Medical Technologies: Canadian developer of the Revanesse line of HA dermal fillers distributed internationally to medical aesthetic clinics — comparable mid-sized competitor with a focused injectable portfolio.
- BioScience GmbH (HYACorp): German manufacturer of HYACorp HA body and facial fillers distributed to aesthetic practitioners across Europe — comparable European private competitor with a similar HA-filler-led portfolio targeting the same professional channel.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Pluryal social profiles
Digital presencePluryal compliance and trust
Trust signalCompliance2 records
Pluryal financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pluryal leadership team
Management profileNumber of profiles
Pluryal funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pluryal M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pluryal
What does Pluryal do?
No factual source-supported description of the company's core offering is present in the provided input. The input block contains no source-attributable product or service description for Pluryal.
Is Pluryal a public or private company?
Pluryal is a private company. It is classified as unknown and is currently operating.
When was Pluryal founded?
Pluryal was founded in 1999. It employs 11 to 50 people.
Where is Pluryal based?
Pluryal is headquartered in Luxembourg, Luxembourg, in the Europe region.
How does Pluryal make money?
Two revenue lines are on record. Medical Aesthetic Products are the primary driver. The others are distributor Network.
Who are Pluryal's main competitors?
Broad incumbents on record are Galderma, AbbVie (Allergan Aesthetics) and Merz Aesthetics. Direct peers are Teoxane, Sinclair Pharma, Croma-Pharma and IBSA Derma. Emerging players are Revance Therapeutics, Prollenium Medical Technologies and BioScience GmbH (HYACorp).
Does Pluryal have an API?
No public API is recorded for Pluryal.